Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 10,173 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the completion of the sale, the chief executive officer directly owned 392,483 shares of the company’s stock, valued at $2,504,041.54. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Lexeo Therapeutics Price Performance

Shares of LXEO stock opened at $6.29 on Monday. The company has a market capitalization of $459.11 million, a PE ratio of -2.33 and a beta of 1.79. The firm’s 50-day moving average is $8.30 and its two-hundred day moving average is $7.67. Lexeo Therapeutics, Inc. has a 12 month low of $1.45 and a 12 month high of $10.99.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors have recently bought and sold shares of LXEO. Invesco Ltd. acquired a new stake in shares of Lexeo Therapeutics during the fourth quarter worth about $4,598,000. Vestal Point Capital LP increased its stake in Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after buying an additional 1,225,000 shares during the period. Virtus Investment Advisers LLC acquired a new stake in Lexeo Therapeutics during the 4th quarter worth approximately $270,000. Wellington Management Group LLP purchased a new position in Lexeo Therapeutics in the 4th quarter valued at approximately $826,000. Finally, Susquehanna Portfolio Strategies LLC grew its stake in shares of Lexeo Therapeutics by 14.4% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock worth $260,000 after acquiring an additional 3,296 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LXEO. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright decreased their price target on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Chardan Capital reissued a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. Finally, Raymond James Financial began coverage on shares of Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.